Dualitas Therapeutics, Inc. announced a research collaboration and license agreement with Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) to advance novel bispecific antibodies (BsAbs) for immunology & inflammation (I&I) diseases, leveraging Dualitas’ DualScreen Bispecific Discovery Engine.
Deal Snapshot
| Item | Detail |
|---|---|
| Partners | Dualitas Therapeutics, Inc. and Roche Holding AG |
| Agreement Type | Research collaboration and license agreement |
| Therapeutic Focus | Novel bispecific antibodies for immunology & inflammation (I&I) diseases |
| Discovery Platform | Dualitas DualScreen Bispecific Discovery Engine |
| Upfront Payment | US$36.5 million to Dualitas |
| Potential Total Deal Value | Up to US$1 billion, including research, development, and commercial milestone payments |
| Royalties | Tiered royalties on future products |
| Announcement Date | 17 Sep 2026 |
Platform Profile – DualScreen Discovery Engine
- First‑of‑Its‑Kind Platform: The DualScreen discovery engine uniquely enables high‑throughput discovery of proximity biology and novel bispecific antibodies, rapidly optimized into differentiated drug candidates.
- Proximity Biology Expertise: The collaboration will leverage Dualitas’ expertise in proximity biology to develop BsAb candidates with synergistic activities unattainable with conventional therapeutics – dual‑target engagement designed to produce mechanisms beyond single‑agent blockade.
- Deal Economics: Dualitas will receive a US$36.5 million upfront payment and may earn additional milestone payments across research, development, and commercialization, for a potential total deal value of up to US$1 billion, in addition to tiered royalties.
- Pipeline & Targets: Specific bispecific targets, programs, and development timelines were Not disclosed.
Market Impact & Outlook
- Roche’s I&I Strategy: The deal extends Roche’s immunology & inflammation portfolio with bispecific modalities, an area where dual‑targeted biologics are emerging as the next wave after monoclonal antibodies and small molecules.
- Platform Validation: A nine‑figure potential deal with one of the world’s largest biopharma groups validates the DualScreen approach to high‑throughput proximity‑biology discovery and positions Dualitas as a technology‑driven bispecific engine company.
- Bispecific Momentum: The agreement adds to the accelerating global wave of BsAb partnering, where big pharma is paying for differentiated mechanisms of action rather than incremental molecules.
- Capital Position: The US$36.5 million upfront provides non‑dilutive funding to advance Dualitas’ internal discovery and platform development while milestones and royalties create long‑term value linkage to Roche programs.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the research collaboration and license agreement between Dualitas and Roche, including the achievement of research, development, and commercial milestones, potential total deal value, and future royalty income. Actual results may differ materially due to risks including discovery and preclinical outcomes, clinical development, regulatory approvals, commercialization, and competitive dynamics. No product arising from this collaboration has received any marketing authorization.-Fineline Info & Tech
